Long-Term Cooperation Agreement With Celgene

Siegfried and Celgene, the American bio-technology company, have put their existing close cooperation on a firm long-term footing. The agreement, which replaces a cooperation agreement signed in 2006, includes the acquisition of a production building in Pharmapark Siegfried in Zofingen, for which Celgene acquired rights of use including corresponding facilities 10 years ago.  

Siegfried will continue to support Celgene in manufacturing pharmaceutical ingredients, intermediate products and analytics as well as in other technical services. Siegfried CEO Rudolf Hanko: “The close cooperation is attractive for both sides. Celgene benefits from Siegfried AG’s vast experience in the production of pharmaceutical ingredients, while Siegfried puts its customer relationship with one of the world’s most successful biotechnology companies on a firm long-term footing”.

About Siegfried

The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, Germany, China, Malta and the USA. At the end of 2014, Siegfried reported annual sales of CHF 315 million and employs at the time being approximately 1400 employees. The Siegfried Group signed an agreement with BASF of Germany in May 2015 which, in the third quarter of 2015, will lead to the acquisition of three sites in France, Germany and Switzerland today owned by BASF. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).

Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediate steps and controlled substances, and provides development and production services for drugs in finished dosage forms including sterile filling.